Clinical Scorecard: Dual Action for Bausch + Lomb
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease |
| Key Mechanisms | Combination of 5% lifitegrast and perfluorohexyloctane (PFHO) targeting ocular surface inflammation and tear evaporation. |
| Target Population | Adults with dry eye disease |
| Care Setting | Clinical trials |
Key Highlights
- Combination therapy did not meet primary endpoint but showed significant secondary results.
- 41.6% of patients achieved a three-unit or greater improvement in tCFS at Day 15.
- BL1332 demonstrated significant pain reduction in Phase 1b study.
- Phase 3 trial for dual-action therapy will use Day 15 as primary endpoint.
- BL1332 is being evaluated in a Phase 2 study for post-surgical pain.
Guideline-Based Recommendations
Diagnosis
- Assess total corneal fluorescein staining (tCFS) for dry eye disease.
Management
- Consider dual-action therapy for patients not responding to lifitegrast alone.
Monitoring & Follow-up
- Monitor tCFS changes at Day 15 for dual-action therapy.
Risks
- No new safety signals identified in the studies.
Patient & Prescribing Data
Adults with dry eye disease and ocular pain.
Combination therapy uses over 50% less lifitegrast volume than Xiidra.
Clinical Best Practices
- Utilize a randomized, double-masked study design for evaluating new therapies.
- Focus on significant secondary endpoints when primary endpoints are not met.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
